New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
10:27 EDTHEB, TKMR, BCRX, NNVCMapp drug used to treat Ebola patients, CNN reports
A drug made by privately held Mapp Biopharmaceutical was used to treat the two Americans who contracted Ebola, CNN reports, citing a source familiar with details of the treatment. The experimental treatment called ZMapp had never been tried before in a human but had showed promise with monkeys, CNN adds. Shares of Tekmira (TKMR), NanoViricides (NNVC), BioCryst (BCRX) and Hemispherx (HEB) are moving higher in early trading after two Americans were flown home with Ebola. Reference Link
News For TKMR;NNVC;BCRX;HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
13:51 EDTTKMR, BCRXPotential Ebola patient being treated at UC Davis Medical Center, KCRA says
Subscribe for More Information
January 26, 2015
09:56 EDTBCRXBioCryst management to meet with JPMorgan
Meetings to be held in Boston on January 29-30 hosted by JPMorgan.
09:19 EDTBCRXOn The Fly: Pre-market Movers
Subscribe for More Information
08:34 EDTHEBHemispherx reports genetic changes in Ebola may impede potential treatments
Hemispherx Biopharma announced that in a new publication in the journal mBio, scientists at the U.S. Army Medical Research Institute of Infectious Disease, or USAMRIID, Harvard University, and Massachusetts Institute of Technology, or MIT, studied genetic changes in the Ebola virus, or EBOV, circulating in West Africa and concluded that genomic drift of the EBOV over time may be sufficient to block the action of otherwise potential therapies that target EBOV genetic sequences. The types of potential drugs at risk include monoclonal antibodies and small-interfering RNA which are scheduled to be evaluated during the current outbreak. The two platform drugs of Hemispherx, Alferon N and Ampligen, both experimental therapeutics in a setting of Ebola disease, have recently both demonstrated anti-EBOV activity and have mechanisms of action which are multifaceted by working through cellular "molecular cascades" rather than by targeting viral protein or genetic sequences whose specificity is vulnerable to mutational change as reported by the research consortium on January 20. Although none of the experimental drugs have been approved by the FDA, certain of the experimental therapeutics discussed in the USAMRIID/Harvard/MIT report, are being used to treat small numbers of patients under a World Health Organization, or WHO, emergency protocol. The potential impact of genomic drift on development of therapeutics for EBOV disease has already been realized for other pathogenic human virus, such as HIV and influenza. The large genetic and antigenic diversity seen in HIV has been a "major stumbling block" for development of preventative vaccines.
06:59 EDTBCRXBioCryst grants fast track designation for BCX4161
BioCryst announced that the FDA has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of plasma kallikrein in advanced clinical development for the treatment of hereditary angioedema. BioCryst is enrolling HAE patients in the OPuS-2 trial of BCX4161; a double-blind, randomized, placebo controlled trial conducted in the U.S. and certain EU countries, with the goal of demonstrating the efficacy and safety of BCX4161 treatment for 12 weeks in approximately 100 patients with HAE. BioCryst expects to report results from OPuS-2 by the end of 2015.
January 25, 2015
13:57 EDTBCRX, TKMRUK nurse make full recovery from Ebola, WSJ says
Subscribe for More Information
January 23, 2015
10:07 EDTTKMRHigh option volume stocks
High option volume stocks: CE TSM RYAM NOC SNE FXCM LBTYA TKMR LF STT
07:07 EDTNNVCNanoViricides reports positive results of FluCide candidate in toxicology study
Subscribe for More Information
January 22, 2015
16:41 EDTTKMRFalcon Edge Capital reports 9/9% passive stake in Tekmira
Subscribe for More Information
09:54 EDTTKMRTekmira mentioned cautiously by TheStreetSweeper
Subscribe for More Information
07:05 EDTNNVCNanoViricides ships anti-ebola drug candidates for testing to a BSL-4 laboratory
Subscribe for More Information
January 21, 2015
08:34 EDTTKMRTekmira initiates Phase I clinical trial of TKM-HBV
Subscribe for More Information
January 20, 2015
17:09 EDTTKMRRA Capital reports 9.9% passive stake in Tekmira
Subscribe for More Information
January 19, 2015
12:06 EDTTKMRNeurovive: Merger between Oncore and Tekmira includes NVP018 development
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use